Rapid Inverse Planning for Pressure-Driven Drug Infusions in the Brain

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Rosenbluth, Kathryn H ^a   Martin, Alastair J ^c   Mittermeyer, Stephan ^b   Eschermann, Jan ^b   Dickinson, Peter J ^d   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BrainLAB   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; NEURITE PROMOTING FACTOR;

ALGORITHM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANISOTROPY; ARTICLE; BRAIN; BRAIN TUMOR; CANNULA; CONTROLLED STUDY; CORPUS STRIATUM; DIFFUSION WEIGHTED IMAGING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG INFUSION; INTRAOPERATIVE PERIOD; LIGHT DARK CYCLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; PUTAMEN; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SPHEROID CELL; THALAMUS;

ANIMALS; BRAIN; CATHETERS; DOGS; FEMALE; HUMANS; INFUSION PUMPS; MODELS, BIOLOGICAL; PLANNING TECHNIQUES; PRESSURE; TIME FACTORS;

EID: 84874037134     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056397     Document Type: Article

References (38)

1. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, et al. (2000) Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164: 2-14.
2. Daadi MM, Pivirotto P, Bringas J, Cunningham J, Forsayeth J, et al. (2006) Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys. Neuroreport 17: 201-204.
3. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466.
4. Marks WJ, Stacy M (2009) A Phase I/II Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects with Idiopathic Parkinson's Disease). Minutes of the National Institutes of Health Recombinant DNA Advisory Committee.
5. Sampson JH, Archer G, Pedain C, Wembacher-Schroder E, Westphal M, et al. (2009) Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg.
6. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, et al. (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25: 837-844.
7. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, et al. (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100: 472-479.
8. Morrison PF, Lonser RR, Oldfield EH, (2007) Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg 107: 74-83.
9. Valles F, Fiandaca MS, Eberling JL, Starr PA, Larson PS, et al. (2010) Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery 67: 1377-1385.
10. Sampson JH, Raghavan R, Brady ML, Provenzale JM, Herndon JE, et al. (2007) Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro-oncology 9: 343-353.
11. Rosenbluth KH, Eschermann JF, Mittermeyer G, Thomson R, Mittermeyer S, et al. (2012) Analysis of a simulation algorithm for direct brain drug delivery. Neuroimage 59: 2423-2429.
12. Richardson RM, Kells AP, Martin AJ, Larson PS, Starr PA, et al. (2011) Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg 89: 141-151.
13. San Sebastian W, Richardson RM, Kells AP, Lamarre C, Bringas J, et al. (2012) Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther 23: 210-217.
14. Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, et al. (2006) Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14: 564-570.
15. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, et al. (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70: 1980-1983.
16. Salegio EA, Samaranch L, Jenkins RW, Clarke CJ, Lamarre C, et al. (2012) Safety study of AAV2-mediated human acid sphingomyelinase expression in the non-human primate brain. Hum Gene Ther.
17. Salegio EA, Kells AP, Richardson RM, Hadaczek P, Forsayeth J, et al. (2010) Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders. Hum Gene Ther 21: 1093-1103.
18. Su X, Kells AP, Huang EJ, Lee HS, Hadaczek P, et al. (2009) Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 20: 1627-1640.
19. Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, et al. (2011) Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther 19: 1048-1057.
20. Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, et al. (2012) Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol 14: 145-159.
21. Tai CK, Wang WJ, Chen TC, Kasahara N, (2005) Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 12: 842-851.
22. Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, et al. (2008) Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg 108: 989-998.
23. Fiandaca MS, Berger MS, Bankiewicz KS, (2011) The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel) 3: 369-397.
24. Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, et al. (2006) Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 66: 2801-2806.
25. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, et al. (2007) Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol 9: 393-403.
26. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, et al. (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91: 2076-2080.
27. Yin D, Richardson RM, Fiandaca MS, Bringas J, Forsayeth J, et al. (2010) Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg 113: 240-248.
28. Yin D, Valles FE, Fiandaca MS, Bringas J, Gimenez F, et al. (2009) Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage.
29. Yin D, Valles FE, Fiandaca MS, Bringas J, Gimenez F, et al. (2011) Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage 54 (Suppl 1): S196-203.
30. Villard C, Soler L, Gangi A, (2005) Radiofrequency ablation of hepatic tumors: simulation, planning, and contribution of virtual reality and haptics. Comput Methods Biomech Biomed Engin 8: 215-227.
31. Rosenbluth KH, Luz M, Mohr E, Mittermeyer S, Bringas J, et al. (2011) Design of an in-dwelling cannula for convection-enhanced delivery. J Neurosci Methods 196: 118-123.
32. Krauze MT, Saito R, Noble C, Tamas M, Bringas J, et al. (2005) Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 103: 923-929.
33. Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, et al. (2002) Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97: 905-913.
34. Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, et al. (2005) Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol 196: 381-389.
35. Krauze MT, McKnight TR, Yamashita Y, Bringas J, Noble CO, et al. (2005) Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc 16: 20-26.
36. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS, (2008) Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 5: 123-127.
37. Smith Y, Villalba R, (2008) Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Mov Disord 23 (Suppl 3): S534-547.
38. Richardson RM, Kells AP, Martin AJ, Larson PS, Starr PA, et al. (2011) Novel Platform for MRI-Guided Convection-Enhanced Delivery of Therapeutics: Preclinical Validation in Nonhuman Primate Brain. Stereotact Funct Neurosurg 89: 141-151.